Exploring Patient Heterogeneity and Diversity in Treatment Responses
Author: Jennifer Bright, MPA Everyone hopes for a COVID vaccine so our lives can return to normal. Yet, we know that even if clinical trials prove a vaccine's effectiveness, our society will still have to [...]
IVI Releases First Annual Report
IVI is pleased to share our Annual Report that documents the transition of our organization to an independent, 501c(3) organization, describes our membership and patient engagement strategies, and offers highlights and learnings from research and [...]
Jennifer Bright Discusses Her Journey and How to Improve Value Assessment
In an interview with Dr. William Seeds in Authority Magazine, Jennifer Bright talks about her own journey to IVI, what drives her to improve value assessment, and why collaboration is paramount for success. Read the [...]
The Promise of MCDA to Improve Equity in Value Assessment
In a commentary in AJMC, IVI examines how multi-criteria decision analysis has the potential to better understand and assess value for innovative cell and gene therapies which are transforming the lives of patients living with [...]
How do we identify and measure value for patients with rare diseases?
Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and [...]
PRESS RELEASE: IVI Announces Grant to National Health Council, National Alliance of Healthcare Purchaser Coalitions to Improve Value Assessment
Goal: Identify Areas of Consensus to Ultimately Make the Value Assessment Process Useful to Those Who Receive and Pay for Care Alexandria, VA – July 20, 2020 – The Innovation and Value Initiative (IVI), a [...]
How IVI Puts Patients at the Center of Value Assessment
Central to IVI’s work is ensuring patient perspectives are included at the front of all value assessments. This short video explains why and how IVI incorporates lived experience in its modeling.
Can Depression Help Employers Improve Their Value Assessment Methods?
IVI's Jennifer Bright and Mike Thompson of the National Alliance for Healthcare Purchasers share how employers can use depression as a "test case" for thinking about how to improve the value assessment process, so that [...]
Value Assessment During the COVID-19 Pandemic
The COVID-19 pandemic is raising new questions about how we approach value assessment. As always, IVI urges experts to use transparency, real world data, and seek consensus. Sam Nussbaum, President of the IVI Board of [...]
Defining Value Starts with Patients
Authors: Alan Balch and Donna Cryer The vast majority of experts agree that we could, and should, be doing a lot more to include input from patients in value assessment, from conceptualization to data inputs [...]
Why Accounting for Our Differences Matter in Assessing Drug Value
IVI's Jennifer Bright and Amy Miller, former CEO of the Society for Women's Health Research, explain why patient heterogeneity is crucial to consider in any value assessment method. Read the full article here.
Experts Address Gaps in Value Assessment
Previewing their panel discussion at ISPOR 2020, Lou Garrison and Leah Howard discuss what’s needed to address gaps on value assessment. View the short video clip here.